Paris: One person has been left brain-dead and five others hospitalised after a "serious accident" during a drugs trial in France, Health Minister Marisol Touraine said today.
She said the six volunteers had been taking part in a "trial of an oral medication being developed by a European laboratory" in the northwestern city of Rennes.
According to a source close to the case, the drug was a painkiller containing cannabinoids, an active ingredient found in cannabis plants.
A separate source said the research company Biotrial had been carrying out the drugs trial for Portuguese pharmaceutical company Bial.
"A serious accident took place," the minister said, adding that the study had been halted and all volunteers taking part recalled. The incident occurred on Thursday.
The study was a Phase I clinical trial, in which healthy volunteers take a prototype medication to "evaluate the safety of its use, tolerance and pharmacological profile of the molecule", the minister added in a statement.
It was not clear how many people were taking part in the study.
Clinical trials typically have three phases to assess a new drug or medical innovation for safety and effectiveness. Human participation in such trials and scrutiny by outside watchdogs are essential for obtaining market authorisation.
Phase I entails a small group of volunteers, and focuses only on safety.
Phase II and Phase III are progressively larger trials, typically involving hundreds or thousands of volunteers, to assess the drug's effectiveness, although safety remains paramount.
Touraine was set to hold a press conference later today alongside a manager from the Biotrial company which has its French headquarters in Rennes.
The company conducts its Phase I trials at a 150-bed facility in Rennes and also in Newark, New Jersey, from where it carries out "a large variety of early clinical studies," according to its website.
Biotrial says it is able to fast-track early patient studies by "combining the favourable regulatory environment in Western Europe with fast and efficient patient recruitment in Eastern Europe."
The Paris prosecutor's office said an investigation had been opened.
Touraine vowed to "shed light on" what happened and has called for an inspection of the research site.
Every year thousands of volunteers, often students looking to make extra money, take part in such clinical trials which are seen as safe.
Mishaps are relatively rare, but in 2006 six men were hospitalised in London after taking part in a clinical trial into a drug developed to fight auto-immune disease and leukaemia.
In gene therapy, setbacks have included the death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer in two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.
She said the six volunteers had been taking part in a "trial of an oral medication being developed by a European laboratory" in the northwestern city of Rennes.
According to a source close to the case, the drug was a painkiller containing cannabinoids, an active ingredient found in cannabis plants.
"A serious accident took place," the minister said, adding that the study had been halted and all volunteers taking part recalled. The incident occurred on Thursday.
Advertisement
It was not clear how many people were taking part in the study.
Advertisement
Phase I entails a small group of volunteers, and focuses only on safety.
Advertisement
Touraine was set to hold a press conference later today alongside a manager from the Biotrial company which has its French headquarters in Rennes.
Advertisement
Biotrial says it is able to fast-track early patient studies by "combining the favourable regulatory environment in Western Europe with fast and efficient patient recruitment in Eastern Europe."
Advertisement
Touraine vowed to "shed light on" what happened and has called for an inspection of the research site.
Every year thousands of volunteers, often students looking to make extra money, take part in such clinical trials which are seen as safe.
Mishaps are relatively rare, but in 2006 six men were hospitalised in London after taking part in a clinical trial into a drug developed to fight auto-immune disease and leukaemia.
In gene therapy, setbacks have included the death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer in two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.
COMMENTS
Advertisement
"I'll Be Back Soon": Rapper Wiz Khalifa Charged Over Cannabis Possession In Romania Cannabis To Be Re-Listed As A Narcotic By End Of 2024, Says Thai PM We Don't All Smoke Weed In Germany, Chancellor Assures Chinese Students Amid Huge Row, Karnataka Pauses Bill For Reservation In Private Sector Firms Travel Influencer Aanvi Kamdar Dies After Falling Off A Waterfall Near Mumbai "I Divorce You... Your Ex-Wife": Dubai Princess Dumps Husband In Insta Post Biden Says Could Drop Election Bid If "Medical Condition" Emerged Russia Says It's Ready To Work With Any US Leader 3 People Die After Drowning In Lake In Telangana: Cops Track Latest News Live on NDTV.com and get news updates from India and around the world.